Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology and Oncology, is the David H. Johnson Endowed Chair of Surgical and Medical Oncology, Co-Director of GI Oncology and the Co-Leader of the Gastrointestinal Cancer Research Program, VICC Associate Director of Strategic Relations and Research Partnerships, Executive Director of the Young Adults Cancers Program. She was the Ambassador for the American Cancer Society ResearcHERS campaign (2020-2022). She is a highly sought mentor and served on the Vanderbilt-Ingram Mentorship Council and is currently a mentor on the T-32 grant and serves on the Professional Development Mentor. She continues to assume leadership positions devoted to development of phase I-III clinical trials using novel therapeutics for biomarker discovery and enhanced drug utilization in colorectal, appendiceal and anal cancer patients. Nationally, Dr. Eng has also been highly active serving on multiple committees for ASCO, ECOG, and SWOG. She was chosen for the ASCO Leadership Development Program, ASCO Social Media Committee, the ASCO Colorectal Guidelines Committee, ASCO Scientific Program Committee (Colorectal Cancer Track) and the ASCO Communications Committee. She has served as the co-chair of the SWOG Rectal/Anal Cancer Subcommittee; the Vice-Chair for the SWOG GI Committee; the Chairman of the NCI Rectal/Anal Task Force, member of the NCI GI Steering Committee, and is now the co-Chair of the NCI GI Steering Committee. She participated in the President Biden’s Cancer Moonshot White House Colorectal Cancer Forum. She has published in many peer-reviewed journals and served on many national grant review panels.

Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and Associate Director for Translational Research at The Tisch Cancer Institute. Dr. Galsky specializes in the care of patients with genitourinary malignancies—bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies.

Yelena Y. Janjigian MD, is Professor and Chief of Gastrointestinal (GI) Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Her research career and clinical practice are focused on improving treatment outcomes for patients with GI malignancies. She is an international expert in the management of cancers of esophagus and stomach and lead several seminal studies that changed practice and set the standard of care for these diseases. She produced high impact publications describing the genomic basis for esophagogastric cancer pathogenesis and secure federal grants to fund future studies. Her research is focused on developing new treatments, with a special emphasis on defining the therapeutically relevant molecular characteristics of tumors in the GI tract, with 120 peer-reviewed publications to date. Dr. Janjigian received her BS from the University of California, San Diego and her MD from the New York University School of Medicine. She did her internal medicine residency at New York School of Medicine/Bellevue Hospital and her hematology/oncology fellowship training at MSKCC. She joined the MSK faculty in 2009 as a member of the GI Oncology Service. Dr. Janjigian is an active member of American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and European Society for Medical Oncology (ESMO) holding an array of leadership positions. As Chief of the GI Oncology Service, Dr. Janjigian’s mission is to foster research and innovation that transform the future of GI oncology to help patients worldwide.

Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987. Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is Co-Chair of the Medical Oncology Committee for NRG Cooperative Oncology Group and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). Since 2016, he has been Editor-in-Chief of the International Lung Cancer News (ILCN) under the aegis of the IASLC.

Kelly E. McCann, MD, PhD, is an Assistant Professor of Medicine in the Division of Hematology/Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). She earned her medical degree and her PhD in Cancer Biology studying DNA double-strand break repair by homologous recombination at Stanford University School of Medicine in California. She completed an internship and residency in Internal Medicine at Oregon Health & Science University in Portland and fellowships in Hematology and Oncology at UCLA. Dr. McCann is board-certified in Internal Medicine, Hematology, and Oncology. Dr. McCann was a member of UCLA’s Translational Oncology Research Laboratories headed by Dr. Dennis Slamon, where she studied mechanisms of PARP inhibitors. Her laboratory research has been published in peer-reviewed journals, including Science, Bioinformatics, and Radiation Research. Her clinical interests are breast cancer, gynecologic oncology, and end of life care. She is a sub-investigator or principal investigator for numerous breast clinical trials at UCLA. She and Sara Hurvitz published a textbook through Elsevier on the biology and treatment of HER2+ breast cancer in August 2018. She has a very strong interest in oncology education, leading to the development of a Solid Oncology curriculum for UCLA Internal Medicine residents and won Teacher of the Year in Hematology/Oncology in 2023. She is a member of the American Medical Association, the American College of Physicians, the American Society of Clinical Oncology, and the American Association for Cancer Research.

Kathleen N Moore, MD, is an Associate Professor in the Section of Gynecologic Oncology; the Jim and Christy Everest Endowed Chair in Cancer Research; and the Director of the Oklahoma TSET Phase I Program for the Stephenson Cancer Center at the University of Oklahoma College of Medicine. She attended medical school at the University of Washington School of Medicine and completed her residency in obstetrics and gynecology at the University Health Center of Pittsburgh. Dr Moore completed a fellowship in gynecologic oncology at the University of Oklahoma Health Sciences Center while simultaneously earning a master's degree in epidemiology. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care. She serves as the Associate Director of Clinical Research and Medical Director of the Clinical Trials Office for the Stephenson Cancer Center. She has published over 200 peer-reviewed publications and serves on the editorial board for four academic publications. She has a clinical research interest in drug development and phase I trials.